Please login or register to print this page.

The British Journal
of Cardiology

This website is intended for healthcare professionals only

Generic clopidogrel imminent

July 2009    Volume 16, Issue 4   Br J Cardiol 2009;16:163-6

Authors:
BJCardio editorial staff

The European Medicines Agency (EMEA) has given a positive recommendation to six generic versions of clopidogrel. Such recommendations are normally endorsed by the European Commission within a few weeks, so generic clopidogrel should be available in most European countries in the very near future.

Four of the six generics are from the Swiss company Acino, one is from the Israeli company Teva, and one from the Greek firm Pharmathen. Generic clopidogrel is already available in Germany.

Clopidogrel, which is sold under the brand name Plavix by Sanofi-Aventis and Bristol-Myers Squibb, was the second-biggest selling drug worldwide in 2008, with sales of more than US$ 8 billion. The generic competitors have been the subject of a long-term patent dispute, and Sanofi-Aventis said it would contest the new generics and defend its intellectual property rights.

In the near future, you will need to be a registered user to view full articles

Already a member? Login now

Register Now

Close

back to top

Comments

There are currently no comments for this article - leave a comment

You must be logged in to post a comment.
Not yet a member? Register now for free.

back to top

Close

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

Find out more about our membership benefits

Close

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.

Find out more about our membership benefits